Compare Citius Pharmaceuticals Inc (CTXR) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs MPLX LP — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while MPLX LP trades at $56.58 (market cap $57.34B). The key difference: MPLX LP is far larger — about 3916.7× Citius Pharmaceuticals Inc's market cap, and MPLX LP pays a 7.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MPLX | |
|---|---|---|
Market Cap | $14.64M | $57.34B |
Sector | Health | Technology |
52-Week High | $1.82 | $59.17 |
52-Week Low | $0.53 | $47.80 |
Enterprise Value | $10.86M | $81.97B |
Dividend Yield | — | 7.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MPLX trades at $57.21, up 0.46% today, with a bullish technical outlook supported by moving averages and a consensus price target of $60.60. The company reported strong profitability with a 41.24% net income margin and robust cash flow from operations of $5.91B in 2025. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 2026 results pending. A dividend of $1.08 was declared for H1-26, reinforcing income appeal.
The stock presents a compelling value with a P/E of 12.23 and high analyst buy consensus (71.43%), though risks include earnings volatility and high debt-to-asset ratio of 90.06%. Upside is supported by stable midstream operations and Permian Basin exposure, but investors should monitor Q2 2026 earnings for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
